Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation

D Pan¹, L-Z Pan¹, R Hill¹, P Marcato¹, M Shmulevitz¹, LT Vassilev² and PWK Lee*,1,3

¹Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4R2; ²Discovery Oncology, Roche Research Center, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, Nj 07110, USA; ³Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4R2

BACKGROUND: Naturally oncolytic reovirus preferentially kills cancer cells, making it a promising cancer therapeutic. Mutations in tumour suppressor p53 are prevalent in cancers, yet the role of p53 in reovirus oncolysis is relatively unexplored.

METHODS: Human cancer cell lines were exposed to Nutlin-3a, reovirus or a combination of the two and cells were processed for reovirus titration, western blot, real-time PCR and apoptosis assay using Annexin V and 7-AAD staining. Confocal microscopy was used to determine translocation of the NF-κB p65 subunit.

RESULTS: We show that despite similar reovirus replication in p53+/+ and p53−/− cells, stabilisation of p53 by Nutlin-3a significantly enhanced reovirus-induced apoptosis and hence virus release and dissemination while having no direct effect on virus replication. Enhanced apoptosis by Nutlin-3a was not observed in p53−/− or p53 knockdown cells; however, increased expression of Bax and p21 are required. Moreover, elevated NF-κB activation in reovirus-infected cells following Nutlin-3a treatment was necessary for enhanced reovirus-induced apoptosis, as synergistic cytotoxicity was overcome by specific NF-κB inhibitors.

CONCLUSION: Nutlin-3a treatment enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation, and combination of reovirus and Nutlin-3a might represent an improved therapy against cancers harbouring wild-type p53.

Keywords: reovirus; Nutlin-3a; p53; NF-κB; apoptosis

Mammalian reovirus is a benign virus that has long been used as a model to study virus–host interactions. Reovirus was discovered preferentially replicate in cancer cells and later shown to target cells with aberrant Ras-signalling pathways, suggesting that reovirus has the potential applicability as an oncolytic therapy (Hashiro et al., 1977; Duncan et al., 1978; Coffey et al., 1998; Strong et al., 1998). Indeed, in vitro and in vivo studies using human tumour xenografts in mice show that reovirus can induce regression of many cancers, including breast cancer, ovarian cancer and lymphoma (Wilcox et al., 2001; Alain et al., 2002; Hirasawa et al., 2002, 2003; Norman et al., 2002). Currently, reovirus (Reolysin) is entering phase III clinical trials in the United States and the United Kingdom for head and neck cancer (Bell, 2010).

Our group and others have reported that the extent of reovirus-induced apoptosis is significantly higher in Ras-transformed cells relative to untransformed cells (Smakman et al., 2005; Marcato et al., 2007; Shmulevitz et al., 2010). As reovirus-induced apoptosis plays an important role in virus cell-to-cell spread and tumour clearance, strategies that enhance apoptosis in cancer cells should promote reovirus oncolysis. Indeed, combining reovirus treatment with radiotherapy or chemotherapies has been shown to significantly enhance cancer cell apoptosis compared to single reagent treatment alone (Twigger et al., 2008; Pandha et al., 2009; Sei et al., 2009).

The tumour suppressor protein p53 plays a major role in dictating the fate of a cell upon exposure to stress or genomic damage, and mutant forms of this protein are found in over 50% of human cancers (Dey et al., 2008). A major effort in combating human cancer is therefore directed at restoring p53 tumour suppressor functions in cancers harbouring aberrant p53 response (Dey et al., 2008; Brown et al., 2009). An important negative regulator of p53 is the murine double minute 2 (MDM2) protein, which targets p53 for proteosomal degradation and which also inhibits p53 transcriptional activity. Nutlin-3a is the active enantiomer of Nutlin-3, a small molecular antagonist of MDM2. Nutlin-3a has been shown to induce p53 accumulation in human cancers that contain wild-type p53 and consequently promote cancer regression (Vassilev et al., 2004; Tovar et al., 2006).

Although the involvement of Ras signalling in reovirus oncolysis has been thoroughly investigated, the possible role of p53 in reovirus oncolysis remains relatively undefined (Huang et al., 2004; Kim et al., 2010). This study shows that reovirus replication, cell-to-cell spread and the extent of reovirus-induced apoptosis are comparable in p53 wild-type (p53+/+) human colon cancer HCT116 cells and their p53-null derivative (p53−/−). However, stabilisation of p53 by Nutlin-3a treatment significantly enhances reovirus-induced apoptosis and cell-to-cell spread in HCT116 p53−/− cells as well as in a variety of human cancer cells containing wild-type p53. We demonstrate that this enhanced cytotoxicity corresponds with the elevated expression of p53 target genes and is dependent on NF-κB activation. These studies suggest that combined reovirus and Nutlin-3a treatment could prove to be

*Correspondence: Dr PWK Lee; E-mail: Patrick.lee@dal.ca
Received 29 March 2011; revised 4 July 2011; accepted 26 July 2011; published online 23 August 2011
superior to single-agent treatment in cancers that retain p53 function.

**MATERIALS AND METHODS**

**Cell lines, reovirus and reagents**

HCT116 cells (parental p53+/+ / p53−/−, PUMA−/−, Bax−/−, P21−/−, PUMA+/−/− and Bax+/−/−/−) were a gift from Dr Bert Vogelstein (John Hopkins University, Baltimore, MD, USA); A549, U2OS and L929 cells were from American Type Culture Collection (Manassas, VA, USA). Reovirus (Serotype 3-Dearing, T3D) was propagated in L-929 culture and purified as established procedures (Smith et al, 1969). Reovirus activity was determined by standard plaque titration.

Nutlin-3a was provided by Hoffmann-La Roche Inc. (Nutley, NJ, USA); RITA (reactivation of p53 and induction of tumour cell apoptosis), Z-VAD(OMe)-FMK (ZVAD), Insoluble NF-κB activation inhibitor (N) and InSolution BAX 11-7082 (B) were purchased from Calbiochem (San Diego, CA, USA); propidium iodide (PI) from Sigma-Aldrich (St Louis, MO, USA); and soluble DR4, DR5 and anti-TRAIL antibody from R&D Systems (Minneapolis, MN, USA).

Antibodies against p53 (Do-I), β-actin, p65, PUMA, Bax and p21 were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).

**Immunostaining for NF-κB p65 nuclear translocation**

Cells grown overnight on gelatin-coated cover slides were treated with Nutlin-3a, reovirus or both. At 12 h-post-infection (hpi), cells were fixed and then stained with anti-p65, anti-reovirus antibodies, followed by Alexa Fluor 488 F(ab′)2, fragment of goat anti-rabbit IgG (H + L), Cy3 AffiniPure Goat Anti-Mouse IgG (H + L) (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) and To-Pro-3 (Invitrogen Canada, Burlington, ON, Canada) for nuclear staining. Images were captured with a Zeiss LSM 510 laser scanning confocal microscope.

**Apoptosis assay, sub-G1 profiling and fluorescence-activated cell sorting analysis**

Unless otherwise indicated, at 24 hpi, cells cultivated in the presence or absence of inhibitors were harvested and stained with Annexin V-FITC and 7-AAD (BD Pharmingen, Oakville, ON, Canada) according to the manufacturer’s instructions. Cell death was quantified by flow cytometry using a FACScan flow cytometer (BD Biosciences, San Jose, CA, USA).

For sub-G1 profiling, cells were fixed with 70% ice-cold ethanol for 30 min, washed with PBS and then stained with PI fluorescence staining buffer (50 μg ml−1 of PI, 20 μg ml−1 RNase A and 0.5% BSA) for 30 min. Two million cells were sorted and quantified by fluorescence-activated cell sorting (FACS) and analysed using WinMDI Version 2.8.

**Transfection and shRNA construct**

Plasmids were transfected with Lipofectamine 2000 transfection reagent (Lipo) (Invitrogen) at a 1:3 ratio of DNA: Lipo according to the manufacturer’s instruction. Specifically, 1.6 μg of pcDNA3 (Invitrogen) or pcDNA3-p53 was transfected into HCT116 cells in the absence of AA. The same ratio of DNA: Lipo was used to transfect retroviral vector pSMP with either scrambled sequence or p53-specific shRNAmir sequence (V2HS_95615, Open Biosystems; Thermo Fisher Scientific Inc., Huntsville, AL, USA) into a packaging cell line as per the manufacturer’s instructions and the resulting retrovirus supernatants were applied to A549 or U2OS cells with 2 μg ml−1 Sequa-brene. Stable cells were selected by the addition of 2 μg ml−1 puromycin at 48 h-post-reovirus.

**RNA extraction and real-time quantitative polymerase chain reaction**

RNAs were extracted with TRIzol and PureLink RNA mini-column (Invitrogen). RNAs were reverse transcribed using the Superscript II reverse transcriptase kit (Invitrogen). Quantifast SYBR RT-PCR kit (Qiagen, Mississauga, ON, Canada) and gene-specific primers (Supplementary Table S1) were used to quantify gene expression as per the manufacturer’s instruction. Standard curves were generated to calculate relative level of mRNA and GAPDH is used as an internal control.

**Dual-luciferase assay**

HCT116 cells (1 × 10⁶ cells/well in six-well plates) were transfected with 3.1 μg pNF-kB-luc (Clontech Laboratories Inc., Mountain View, CA, USA) and 0.08 μg pGL4.74 (Promega, Madison, WI, USA) 24 h before Nutlin-3a treatment. At 6 h-post-transfection, one out of four cells were divided into 12-well plates and allowed to settle until 24 h-post-transfection. Cells were then treated with vehicle (DMSO) or Nutlin-3a and at 6 h-post-treatment infected by reovirus. Cells were lysed by passive lysis buffer (Dual luciferase assay kit; Promega) at indicated time and the collected lysates were flash-frozen and kept in −80°C until use. Luciferase activity was measured by a GloMax Luminometer (Promega).

**Calculation of IC₅₀**

Promega CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega) was used to determine the viability of reovirus- and/or Nutlin-3a-treated cells according to the manufacturer’s instruction. Specifically, 1.5 × 10⁵ cells per well of HCT116 p53+/+ or p53−/− cells were seeded onto 96-well plates at a volume of 100 μl. Reovirus (serial dilution from an MOI of 100 to 1 × 10⁻²) was used to infect cells in triplicate wells after they were treated with 5 μM Nutlin-3a for 6 h. At 48 hpi, 20 μl of the MTS and PMS reagent mixture (20:1) was added to each well using multi-channel pipette and the plate was incubated at 37°C for 1 h before being read at 492 nm by an ELISA microplate reader. IC₅₀ was calculated using GraphPad Prism v.4.

**RESULTS**

**p53 stabilisation by Nutlin-3a enhances reovirus-associated cell death and release of progeny virions**

The prominent function of p53 in regulating apoptosis raised the possibility that p53 status might influence reovirus-mediated apoptosis. To address this question, we compared the efficiency of reovirus replication in HCT116 cells containing constitutively activated K-Ras (Fearon et al, 1990) and wild-type p53 (p53+/+) vs their p53-null isogenic derivative (p53−/−) cells (Bunz et al, 1998). By 18 hpi, total virus titres were comparable between HCT116 p53+/+ cells and HCT116 p53−/− cells, indicating that deletion of p53 did not affect reovirus production (Figure 1A).

To test whether accumulation/activation of p53 can alter reovirus replication in cancer cells, HCT116 (p53−/−) cells were treated with Nutlin-3a. As expected, 5 μM Nutlin-3a caused immediate (within 3 h) and significant p53 accumulation, and increased the expression of p53-regulated p21 and PUMA by 6 h post-treatment (Supplementary Figure S1A). Similarly, levels of p53 were significantly increased with the addition of Nutlin-3a in U2OS cells within 6 h (Supplementary Figure S1B). Cells were therefore treated with 5 μM Nutlin-3a for 6 h before reovirus infection and total reovirus titres were measured at 18 hpi. Levels...
of p53 were markedly increased by Nutlin-3a treatment regardless of reovirus infection (Figure 1A). Moreover, p53 accumulation induced by Nutlin-3a treatment did not affect total reovirus production (Figure 1A). Overall, the extent of virus production in a single round of replication was impervious to the status of p53 in HCT116 cells.

Virus oncolysis depends not only on efficient virus production in cancer cells, but also on the efficient killing of infected cells, which facilitates both cytotoxicity and release of progeny virus for cell-to-cell spread. Experiments were therefore performed to determine if p53 affects reovirus-induced cytotoxicity and virus release. In the absence of Nutlin-3a, the titres of released (i.e., extracellular) reovirus were similar in p53+/+ and p53−/− HCT116 cells, suggesting that cell death and subsequent virus release were unaffected by p53 deletion (Figure 1B). However, the titres of extracellular reovirus were significantly increased following Nutlin-3a treatment of infected p53+/+, but not p53−/− cells (Figure 1B). The enhanced release of reovirus from infected p53+/+ cells following Nutlin-3a treatment was also accompanied by a significant increase in cytotoxicity (Figure 1C). Cytotoxicity was dependent on productive reovirus replication, as cells treated with UV-inactivated reovirus and Nutlin-3a were relatively healthy (data not shown). Altogether, accumulation of p53 by Nutlin-3a in reovirus-infected cancer cells facilitates cell death, and hence release of progeny virions.

**Nutlin-3a significantly enhances caspase-dependent apoptosis of reovirus-infected cancer cells**

The effects of Nutlin-3a on cytotoxicity of reovirus-infected cells were further characterised using Annexin V and 7-AAD staining to quantify the extent of early apoptosis and cell death. As shown previously (Tovar et al., 2006), Nutlin-3a alone induced minimal cell death (Figure 2A) in HCT116 cells. However, the percentage of
Enhanced apoptosis caused by the combination of reovirus and Nutlin-3a is p53 dependent

The enhancement of reovirus-induced cell death by Nutlin-3a was significantly higher in p53+/+ than p53−/− HCT116 cells, and was therefore likely mediated directly through p53 rather than potential nonspecific targets in HCT116 cells (Figure 3A). Furthermore, Nutlin-3a had no effects on reovirus-induced apoptosis when p53 was knocked down in A549 cells using p53-specific shRNA (Figure 3B). Conversely, transient overexpression of p53 in HCT116 p53−/− cells using a p53-expression plasmid resulted in significantly higher levels of reovirus-induced apoptosis (Figure 3C). These studies show that p53 accumulation, whether induced by reovirus or by Nutlin-3a treatment or by transient overexpression, is responsible for enhanced apoptosis of cancer cells induced by reovirus.

Another small molecule, RITA, was also used to induce p53 accumulation. Reactivation of p53 and induction of tumour cell apoptosis inhibits specific interactions between MDM2 and p53 similar to Nutlin-3a, but unlike Nutlin-3a, RITA binds p53 rather than MDM2 (Issaeva et al., 2004). As shown in Figure 3D, treatment of HCT116 p53−/− cells with RITA induced accumulation of p53, which significantly enhanced apoptosis compared to reovirus infection alone. The enhancement of apoptosis induced by RITA treatment was not observed in HCT116 p53+/+ cells. These results suggest that reovirus oncolysis could be enhanced by RITA, Nutlin-3a or other prospective drugs that promote p53 accumulation.

Enhanced apoptosis induced by the combination of Nutlin-3a and reovirus requires Bax and p21

As the enhancement of apoptosis induced by the combination of Nutlin-3a and reovirus is p53-dependent, we wanted to determine whether expression of p53 target genes was enhanced by the combination of Nutlin-3a and reovirus. RNA samples were collected at 24 hpi and subjected to real-time quantitative polymerase chain reaction (real-time qPCR) using primers specific for Noxa, PUMA, Bax and p21 (Supplementary Table S1). As expected, Nutlin-3a treatment alone induced increased expression of these p53 target genes PUMA, Bax and p21, although the upregulation of Noxa was not as drastic. PUMA and Noxa were upregulated by reovirus infection alone. When Nutlin-3a and reovirus were combined, expression levels of proapoptotic genes Noxa, PUMA and Bax were further increased in p53+/+ cells (Figure 4A–C). As reovirus alone had minimal effect on p21 expression, it is not surprising that the already elevated level of antiapoptotic p21 by Nutlin-3a treatment alone was not further enhanced by the combination treatment (Figure 4D). Therefore, combined Nutlin-3a and reovirus treatment had a more pronounced effect on the expression of proapoptotic genes than
proarrest genes at 24 hpi when apoptosis was the desirable outcome.

To further characterise p53 target genes that were important for the enhancement of apoptosis induced by the combination of Nutlin-3a and reovirus, we obtained a panel of knockout cells derived from HCT116 (p53+/+) from Dr Vogelstein (Supplementary Figure S3A). These cells were treated with Nutlin-3a, reovirus or the combination of the two and apoptosis levels were assayed as described before. Status of PUMA or Noxa did not seem to affect the enhancement of apoptosis induced by Nutlin-3a and reovirus (Figure 4E and Supplementary Figure S3C, right panel). Interestingly, although levels of cell death induced by reovirus alone did not significantly vary among all the knockout cells compared to p53+/+ cells (Supplementary Figure S3B), levels of apoptosis induced by the combination of Nutlin-3a and reovirus were significantly decreased in Bax−/− and p21−/− cells. A further decrease in apoptosis level was observed in Bax−/−p21−/− cells (Figure 4E), indicating that both Bax and p21 were required for the p53-dependent enhancement of apoptosis induced by Nutlin-3a and reovirus. The upregulation of proarrest p21 by Nutlin-3a might have blocked apoptosis at earlier times to allow reovirus to replicate efficiently, whereas enhanced Bax expression by Nutlin-3a and reovirus combined at later times would promote apoptosis for virus release.
Apoptosis induced by Nutlin-3a and reovirus requires NF-κB activation

It has previously been demonstrated that reovirus infection causes NF-κB activation. Furthermore, NF-κB was shown to be necessary for reovirus-induced apoptosis, as inhibition of NF-κB activation through disruption of IκB degradation caused diminished reovirus-induced apoptosis. Cells deficient for either p50 or p65 subunits of NF-κB were also found to be resistant to reovirus infection (Connolly et al, 2000; Clarke et al, 2003). We found that

**Figure 4** Differential expression levels of p53 target genes (A) Noxa, (B) PUMA, (C) Bax or (D) p21, induced by reovirus, Nutlin-3a or the combination of the two. Total RNA extracted from HCT116 p53+/+ or p53−/−, with or without Nutlin-3a treatment or reovirus infection for 24 h (as indicated) was assessed for expression levels of GAPDH, Noxa, PUMA, Bax and p21 by real-time qPCR. Levels of genes were normalised to housekeeping gene GAPDH. (E) Fold difference of HCT116 knockout cells’ apoptosis induced by the combination of Nutlin-3a and reovirus compared with HCT116 p53+/+ cells. Percentage of apoptosis induced by Nutlin-3a and reovirus in the knockout cells were normalised to p53+/+ cells (n = 4, ± s.e.m.). Student’s t-test was used to compare two groups of data; NS: not significant; *P < 0.05; **P < 0.001.
**Figure 5** Cell death induced by Nutlin-3a and reovirus requires NF-κB activation. Levels of NF-κB transcription activity after reovirus infection in HCT116 p53+/+ cells (A) and U2OS cells (C) (n = 4, ± s.e.m.). HCT116 cells were infected at an MOI of 1 and lysates were collected at 12 hpi. U2OS cells were infected at an MOI of 500 and lysates were collected at 48 hpi. (B) Nutlin-3a treatment enhanced levels of NF-κB p65 nuclear translocation. Arrows point to infected cells. (D) NF-κB activation inhibitor N (InSolution NF-κB activation inhibitor at 1:100,000 dilution) treatment reduced the level of cell death induced by the combination of reovirus and Nutlin-3a in p53+/+ HCT116 cells. Cell death was determined by quantifying the sub-G1 population of PI-stained cells. Student’s t-test was used to compare two groups of data; NS: not significant; *P < 0.05; **P < 0.001.
reovirus infection alone caused activation of NF-κB transcription in both p53+/+ and p53−/− cells using a dual-luciferase assay, whereas Nutlin-3a alone had negligible effect on the activation of NF-κB (Figure 5A and C and Supplementary Figure S4A and B). When cells were challenged by the combination of reovirus and Nutlin-3a, however, the level of NF-κB transcription activation was further increased in p53+/+ cells (wild-type HCT116 and U2OS cells), but not in p53−/− HCT116 cells, indicating that the enhancement of NF-κB activation caused by Nutlin-3a and reovirus was p53-dependent. In accordance with our results shown above, immunostaining of NF-κB subunit p65 (Figure 5B) showed that Nutlin-3a itself did not affect p65 localisation; reovirus infection clearly induced nuclear translocation of p65 in both p53+/+ and p53−/− cells. However, the addition of Nutlin-3a significantly enhanced the nuclear localisation of p65 in p53+/+ cells, but not in p53−/− cells, further confirming that the combination of reovirus and Nutlin-3a could induce significantly higher level of NF-κB activation and the enhancement is p53-dependent. Furthermore, when NF-κB activation was prevented by NF-κB activation inhibitors, evidenced by the blockage of p65 nuclear translocation (Supplementary Figure S4C and D), cell death of p53+/+ HCT116 cells cotreated with reovirus and Nutlin-3a was significantly reduced (Figure 5D and Supplementary Figure S4D). These results suggest that the cytotoxicity caused by the combination of reovirus and Nutlin-3a is mediated through activation of NF-κB signalling pathways. We further determined the RNA levels of representative p53 target genes with or without the treatment of NF-κB inhibitor N. As shown in Figure 6, inhibition of NF-κB clearly suppressed the upregulation of these genes with the treatment of reovirus and Nutlin-3a. Therefore, the p53-dependent NF-κB activation likely plays a role in controlling the upregulation of p53 target genes, indicating a link between NF-κB activation and the enhancement of apoptosis in Nutlin-3a- and reovirus-treated cells.

Clarke et al (2000) showed that reovirus-induced apoptosis requires proapoptotic signalling through extracellular TRAIL and its receptors DR4 and DR5 in certain cell types. As Nutlin-3 can upregulate the expression and externalisation of TRAIL receptor DR5 (Hori et al, 2009), the involvement of TRAIL was investigated. Anti-TRAIL antibody and competitive soluble DR4 and DR5 ligands were used to subdue the extrinsic TRAIL response, and effectively prevented cell death caused by exogenously added TRAIL (Supplementary Figure S5A). However, anti-TRAIL antibody and competitive DR4- and DR5-soluble ligands did not prevent apoptosis induced by either reovirus or the combination of reovirus and Nutlin-3a (Supplementary Figure S5B). Therefore, the extrinsic TRAIL-mediated pathway does not seem to play a major role in the enhancement of apoptosis induced by reovirus and Nutlin-3a.

Combination of Nutlin-3a significantly increases reovirus-induced cytotoxicity to cancer cells and promotes virus dissemination

As the combination of Nutlin-3a and reovirus is significantly more cytotoxic to cancer cells, we wanted to explore the possibility of using reovirus and Nutlin-3a as a combination therapy for cancers with wild-type p53. To investigate whether Nutlin-3a could improve the efficacy of reovirus, different doses of reovirus were used to infect HCT116 cells in the presence or absence of 5 μM...
Nutlin-3a and IC50 of reovirus was calculated accordingly. As shown in Figure 7A, Nutlin-3a drastically reduced the IC50 of the input reovirus (from 1.4 to 0.22 MOI) in HCT116 p53+/+ cells while having negligible effect on p53-/0 cells. Therefore, the combination of reovirus and Nutlin-3a has the potential as a combination therapy in p53+/+ cancer.

In addition to cytotoxicity, viral oncolysis relies on efficient cell-to-cell spread of virus to overcome the growing tumour. The increased cytotoxicity of reovirus-infected cells and augmented release of new progeny virions by Nutlin-3a suggests that Nutlin-3a could facilitate both cytotoxicity and rapid viral dissemination among tumour cells. Virus cell-to-cell spread can be easily visualised with a virus plaque assay, where agar overlay restricts virus infection only among neighbouring cells. The size of the plaque reflects the extent of virus dissemination over several rounds of replication, release and re-infection (Marcato et al, 2007). As shown in Figure 7B, reovirus plaques formed on Nutlin-3a-treated HCT116 p53+/+ cells were significantly bigger than the ones on vehicle-treated cells, indicating that Nutlin-3a could enhance the spread of reovirus to the neighbouring cells. The enlargement of reovirus plaques by Nutlin-3a was also observed in U2OS control cells, but not p53-shRNA knockdown cells (Figure 7C). Taken together, these results suggest that Nutlin-3a co-treatment confers two advantages important for viral oncolysis; Nutlin-3a supports increased killing of p53+/+ cancer cells and subsequently also permits rapid reovirus dissemination.

**DISCUSSION**

Our study is the first to report that the combination of drugs that cause p53 accumulation and reovirus can induce enhanced cytotoxicity in cancer cells. Although the status of p53 in HCT116 tumour cells does not affect reovirus production, the intact function of p53 in cancer cells can be utilised to promote reovirus-mediated, caspase-dependent apoptosis of cancer cells.

Recently, Kim et al (2010) reported that lack of p53 in certain cells render them susceptible to reovirus infection. Our data showed that there was no significant difference between the HCT116 p53+/+ and p53-/0 cells in reovirus production within at least the first round of reovirus infection (18 hpi; Figure 1A) and the level of apoptosis induced by reovirus was not significantly different between p53+/+ and p53-/0 HCT116 cells or between A549 control and p53 knockdown cells (Figure 3A and B). Therefore, p53-dependent resistance of tumour cells might be cell type-dependent. Moreover, for less susceptible cancer cells (e.g., U2OS), when combined with reovirus, Nutlin-3a treatment clearly induced higher levels of apoptosis and reovirus spread (Figure 2B).
and 7C). Therefore, our results indicate that irrespective of the effects of wild-type p53 on reovirus infection, p53 accumulation with Nutlin-3a treatment ultimately promotes reovirus-mediated cancer cell killing.

The NF-κB transcription factor plays an important role in regulating apoptosis and appears to be involved in a mechanism by which reovirus and Nutlin-3a synergise for increased cancer cell killing. NF-κB was clearly induced by the combination of reovirus and Nutlin-3a in a p53-dependent manner, and induction of NF-κB was required for the full cytotoxic potential of reovirus and Nutlin-3a co-treatment. It was previously reported that NF-κB is essential for p53-dependent apoptosis and that p53 can enhance the activation of NF-κB (Ryan et al, 2000, 2004). In our study, we showed that certain p53 target genes were upregulated by the combination of Nutlin-3a and reovirus, among which, p21 and Bax seem to play a bigger role in promoting cell death induced by the combination of the two agents, as p21 and Bax expression levels had a significantly decreased level of apoptosis. Moreover, inhibition of NF-κB activation by treatment of NF-κB inhibitor was shown to suppress the upregulation of p53 target genes with the treatment of reovirus and Nutlin-3a, further confirming the link between the enhancement of NF-κB activation and the increase in cytotoxicity induced by the combination of p53 accumulation and reovirus infection.

The majority of existing chemotherapy reagents function by causing damage to cells with the premise that highly dividing cancer cells are more prone to the cytotoxic effects. Unfortunately, chemotherapy reagents also damage normal cells and result in various side effects that reduce the quality of life of cancer patients. Attempts are ongoing to reduce unwanted side effects of cancer therapies through alternative cancer treatments and/or through combinations of distinct cancer therapeutics at reduced dosages. Concurrently, reovirus and other oncolytic viruses are being tested as cancer therapeutics. Reovirus is a promising anticancer therapy and phase I clinical trials of reoviruses showed limited toxicity towards patients (Forsyth et al, 2008; Vidal et al, 2008; Harrington et al, 2010). Nutlin-3a was also found to exhibit no pathological effect in in vivo murine studies (Vassilev et al, 2004). According to our results, the combination of the two low-toxic reagents (reovirus and Nutlin-3a) could be an alternative way of inducing cancer regression without exposing cancer patients to unwanted side effects.

Previous studies that combining reovirus with chemotherapeutics did not address that role of p53 in the outcome of the combination (Pandha et al, 2009; Sei et al, 2009). Our results, however, raise the possibility that status of p53 in cancer cells might have effects on combination of chemotherapy drugs with reovirus. Determining whether combination of chemotherapy drugs with reovirus has differential effect on p53野生型和p53突变型 would be important to direct personalised cancer therapy in the future.

ACKNOWLEDGEMENTS

This work was supported by operating grants from the Canadian Institutes for Health Research (CIHR) and the Canadian Cancer Society Research Institute through the Terry Fox Foundation (CCSRI and TFRI) to PWKL, doctoral scholarships from the Cancer Research Training Program (CRTP) (DP) and postdoctoral fellowships from the Alberta Heritage Foundation for Medical Research (FM), CRTP (FM, MS, RH), CIHR (MS) and the National Cancer Institute of Canada (MS).

Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)

REFERENCES

Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, Auer Y, Luider J, Martin A, Johnston RN, Janowska-Wieczorek A, Lee PW, Kossowska AE (2002) Reovirus therapy of lymphoid malignancies. Blood 100: 4146 – 4153
Bell J (2010) Oncolytic viruses: an approved product on the horizon? Mol Ther 18: 233 – 234
Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9: 862 – 873
Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Zhan S, Verma CS, Waisman DM, Lee PW (2003) Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 63: 348 – 353
Brown MR, Stanish SM, Cox DC (1978) Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 28: 444 – 449
Burrington KL, Stanish SM, Cox DC and Hamilton M (2008) A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 16: 627 – 632
Cairncross G, Matthews MV, Markert J, Gillespie Y, Thompson BG, Yoon M, Williamson CT, Prudhomme J, Bebb DG, Riabowol K, Lee PW, Vassilev LT, Kioshima K, Kaiser F, Vassilev ML (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Cancer Res 64: 4907 – 4915
Clarke P, Meintzer SM, Gibson S, Widmann C, Garrington TP, Johnson GL, Tyler KL (2000) Reovirus-induced apoptosis is mediated by TRAIL. J Virol 74: 8135 – 8139
Dey A, Verma CS, Lane DP (2008) Updates on p53 accumulation with Nutlin-3a treatment ultimately promotes reovirus-mediated cancer cell killing. J Virol 82: 1332 – 1334
Dey A, Verma CS, Lane DP (2008) Updates on p53 accumulation with Nutlin-3a treatment ultimately promotes reovirus-mediated cancer cell killing. J Virol 82: 1332 – 1334
Dey A, Verma CS, Lane DP (2008) Updates on p53 accumulation with Nutlin-3a treatment ultimately promotes reovirus-mediated cancer cell killing. J Virol 82: 1332 – 1334
Forsyth PA, Roldan G, George D, Wallace C, Palmer CA, Morris D, Cairncross G, Matthews MV, Markert J, Gillespie Y, Coffey M, Thompson B, Hamilton M (2008) A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 16: 627 – 632
Harrington KJ, Karapapaniagou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, DeBono JS, Melcher AA (2010) Two-stage phase I dose-exploration study of intratumoral reovirus type 3 degrading and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 16: 3067 – 3077
Hashiro G, Loh PG, Yau JT (1977) The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 54: 307 – 315
Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossowska A, Lee PW (2002) Oncolytic reovirus against ovarian and colon cancer. Cancer Res 62: 1696 – 1701
Hirasawa K, Nishikawa SG, Norman KL, Coffey MG, Thompson BG, Yoon CS, Waisman DM, Lee PW (2003) Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 63: 348 – 353
Huang S, Qu LK, Koromilas AE (2004) Induction of p53-dependent apoptosis in HCT116 tumor cells by RNA viruses and possible implications in virus-mediated oncolysis. Cell Cycle 3: 1045 – 1049
Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Lain S, Verma CS, Waisman DM, Lee PW, Verma CS, Waisman DM, Lee PW (2003) Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 63: 348 – 353
Kim M, Williamson CT, Prudhomme J, Bebb DG, Riabowol K, Lee PW, Lees-Miller SP, Mori Y, Rahman MM, McFadden G, Johnston RN (2010) The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is determined in situ. J Gen Virol 91: 1021 – 1029
Kinzler KW, Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497 – 1501
Kumar V, Cheema J, Henry CA, Sato T, Egan AM, Finlayson C, Telford J, Kramer J, Anisuzzaman T, Vassala M, Parada L, Hockley D, Trepel D, Gattil T, Chilvers E, Nishioka J, Vassilev LT, Kioshima K, Kaiser F, Vassilev ML (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Cancer Res 64: 4907 – 4915
Lees-Miller SP, Mori Y, Rahman MM, McFadden G, Johnston RN (2010) The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is determined in situ. J Gen Virol 91: 1021 – 1029
Panthapun S, Nowell P, Luider J, Martin A, Johnston RN, Janowska-Wieczorek A, Lee PW, Kossowska AE (2002) Reovirus therapy of lymphoid malignancies. Blood 100: 4146 – 4153
Pandha HS, Zhang Q, Sei PWKL, Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossowska A, Lee PW (2003) Oncolytic reovirus against ovarian and colon cancer. Cancer Res 63: 348 – 353
Pramanik A, Selivanova G (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Cancer Res 64: 4907 – 4915
Ryan ET, Kioshima K, Kaiser F, Vassilev ML (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Cancer Res 64: 4907 – 4915
Sei PWKL, Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossowska A, Lee PW (2003) Oncolytic reovirus against ovarian and colon cancer. Cancer Res 63: 348 – 353
Terry Fox Foundation (CCSRI and TFRI) to PWKL, doctoral scholarships from the Cancer Research Training Program (CRTP) (DP) and postdoctoral fellowships from the Alberta Heritage Foundation for Medical Research (FM), CRTP (FM, MS, RH), CIHR (MS) and the National Cancer Institute of Canada (MS).
virus, is modulated by cellular tumor suppressor gene status. Oncogene 28: 3990–3996
Marcato P, Shmulevitz M, Pan D, Stoltz D, Lee PW (2007) Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 15: 1522–1530
Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, Strong JE, Lee PW (2002) Reovirus oncolysis of human breast cancer. Hum Gene Ther 13: 641–652
Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, Coffey M, Harrington KJ, Morgan R (2009) Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 15: 6158–6166
Ryan KM, Ernst MK, Rice NR, Vousden KH (2000) Role of NF-kappaB in p53-mediated programmed cell death. Nature 404: 892–897
Ryan KM, O’Prey J, Vousden KH (2004) Loss of nuclear factor-kappaB is tumor promoting but does not substitute for loss of p53. Cancer Res 64: 4415–4418
Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC, Shoemaker RH, Tomaszewski JE (2009) Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer 8: 47
Shmulevitz M, Pan LZ, Garant K, Pan D, Lee PW (2010) Oncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-1 signaling. Cancer Res 70: 4912–4921
Smakman N, van den Wollenberg DJ, Borel RI, Hoeben RC, Kranenburg O (2003) Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D. J Virol 77: 14981–14985
Smakman N, van den Wollenberg DJ, Elias SG, Sasazuki T, Shirasawa S, Hoeben RC, Borel RI, Kranenburg O (2006) KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 66: 5403–5408
Smith RE, Zweerink HJ, Joklik WK (1969) Polypeptide components of virions, top component and cores of reovirus type 3. Virology 39: 791–810
Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW (1998) The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17: 3351–3362
Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT (2006) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 103: 1888–1893
Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, Thompson B, Vile RG, Heinemann L, Pandha HS, Errington F, Melcher AA, Harrington KJ (2008) Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res 14: 912–923
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs G, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844–848
Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ, DeBono JS (2008) A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 14: 7127–7137
Wilcox ME, Yang W, Senger D, Newcastle NB, Morris DG, Brasher PM, Shi ZQ, Johnston RN, Nishikawa S, Lee PW, Forsyth PA (2001) Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 93: 903–912

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.